SEARCH:   Advanced

Blood, 1 March 2008, Vol. 111, No. 5, pp. 2516-2520. Prepublished online as a Blood First Edition Paper on November 1, 2007; DOI 10.1182/blood-2007-10-116129. This Article Full Text (PDF) All Versions of this Article: blood-2007-10-116129v1 111/5/2516    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kumar, S. K Articles by Gertz, M. A Search for Related Content PubMed PubMed Citation Articles by Kumar, S. K Articles by Gertz, M. A Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted October 2, 2007 Accepted October 24, 2007 Improved survival in multiple myeloma and the impact of novel therapies Shaji K Kumar*, S. Vincent Rajkumar, Angela Dispenzieri, Martha Q. Lacy, Suzanne R Hayman, Francis K Buadi, Steven R Zeldenrust, David Dingli, Stephen J Russell, John A. Lust, Philip R Greipp, Robert A Kyle, and Morie A Gertz Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN * Corresponding author; email: kumar.shaji{at}mayo.edu. Treatments for myeloma have expanded in the last decade, but it is not clear if the introduction of novel therapies and the increased use of high dose therapy have translated into better outcome for patients with myeloma. We examined the outcome of two groups of patients seen at a single institution, one from time of diagnosis and the other from the time of relapse, to examine the survival trends over time. Among 387 patients relapsing after stem cell transplant, a clear improvement in overall survival from the time of relapse was seen, with those relapsing after 2000 having a median overall survival of 23.9 vs. 11.8 months (P<0.001) for those who relapsed prior to this date. This improvement was independent of other prognostic factors. Patients treated with one or more of the newer drugs (thalidomide, lenalidomide, bortezomib) had longer survival from relapse (30.9 vs. 14.8 months; P<0.001). In a larger group of 2981 patients with newly diagnosed myeloma, those diagnosed in the last decade had a 50% improvement in overall survival (44.8 vs. 29.9 months; P<0.001). In this study, we demonstrate improved outcome of patients with myeloma in recent years, both in the relapsed setting as well as at diagnosis. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: The road to cure in multiple myeloma Irene M. Ghobrial and Kenneth C. Anderson Blood 2008 111: 2503. [Full Text] [PDF] This article has been cited by other articles: E. Terpos, O. Sezer, P. I. Croucher, R. Garcia-Sanz, M. Boccadoro, J. San Miguel, J. Ashcroft, J. Blade, M. Cavo, M. Delforge, et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network Ann. Onc., May 22, 2009; (2009) mdn796v1. [Abstract] [Full Text] [PDF] S. Knop, C. Gerecke, P. Liebisch, M. S. Topp, U. Platzbecker, O. Sezer, C. Vollmuth, K. Falk, A. Glasmacher, U. Maeder, et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom) Blood, April 30, 2009; 113(18): 4137 - 4143. [Abstract] [Full Text] [PDF] E. M. Ocio, P. Maiso, X. Chen, M. Garayoa, S. Alvarez-Fernandez, L. San-Segundo, D. Vilanova, L. Lopez-Corral, J. C. Montero, T. Hernandez-Iglesias, et al. Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks Blood, April 16, 2009; 113(16): 3781 - 3791. [Abstract] [Full Text] [PDF] J. Blade and L. Rosinol Changing paradigms in the treatment of multiple myeloma Haematologica, February 1, 2009; 94(2): 163 - 166. [Full Text] [PDF] H. Brenner, A. Gondos, and D. Pulte Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010 Haematologica, February 1, 2009; 94(2): 270 - 275. [Abstract] [Full Text] [PDF] G. Bisping, D. Wenning, M. Kropff, D. Gustavus, C. Muller-Tidow, M. Stelljes, G. Munzert, F. Hilberg, G. J. Roth, M. Stefanic, et al. Bortezomib, Dexamethasone, and Fibroblast Growth Factor Receptor 3-Specific Tyrosine Kinase Inhibitor in t(4;14) Myeloma Clin. Cancer Res., January 15, 2009; 15(2): 520 - 531. [Abstract] [Full Text] [PDF] P. Moreau, V. Coiteux, C. Hulin, X. Leleu, H. van de Velde, M. Acharya, and J.-L. Harousseau Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma Haematologica, December 1, 2008; 93(12): 1908 - 1911. [Abstract] [Full Text] [PDF] M. Wang, M. A. Dimopoulos, C. Chen, M. T. Cibeira, M. Attal, A. Spencer, S. V. Rajkumar, Z. Yu, M. Olesnyckyj, J. B. Zeldis, et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure Blood, December 1, 2008; 112(12): 4445 - 4451. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020